Treats relapsing forms of multiple sclerosis (MS). ANDA 208003, held by Prinston. Fingolimod Hydrochloride.
As of Nov 16, 2026, ANDA 208003 (Fingolimod Hydrochloride), held by Prinston, was first approved by FDA on Sep 7, 2022, with 1 approved supplement and 0 published complete response letters.
Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 7, 2022 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fingolimod HydrochlorideEQ 0.5MG BASE · capsule;oral | Fingolimod Hydrochloride | Rx |
| Dec 17, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 7, 2022 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters